heptamethine carbocyanine dye-exatecan conjugate

Heptamethine carbocyanine dye-exatecan conjugates are experimental drug constructs that combine a tumor-targeting near-infrared fluorescent (NIRF) heptamethine carbocyanine dye with the cytotoxic agent exatecan. The heptamethine carbocyanine dyes serve as delivery vehicles, exploiting their preferential accumulation in tumor cells—particularly within mitochondria and lysosomes—while sparing normal tissues. This targeting is believed to be mediated by organic anion transporting peptides highly expressed in cancer cells[1][2][4][5]. By linking these dyes to chemotherapeutic agents such as exatecan (a topoisomerase I inhibitor), the resulting drug-dye conjugates aim to enhance selective delivery of cytotoxics to tumors, increase retention at the tumor site, and reduce systemic toxicity. These constructs are under preclinical investigation for applications including primary and metastatic brain tumors and other solid malignancies[1][2][3][4].

Other names

heptamethine cyanine dye-exatecan conjugate